Faculty

Mainly engaged in the clinical diagnosis and treatment of abdominal and pelvic tumors, focusing on the research of comprehensive diagnosis and treatment technologies for recurrence and metastasis of peritoneal tumors and retroperitoneal tumors. Established a new comprehensive diagnosis and treatment model for peritoneal cancer centered on standardized tumor cytoreductive surgery combined with intraperitoneal hyperthermic perfusion chemotherapy. Hosted the formulation of multiple domestic expert consensuses and participated in the formulation of international guidelines related to peritoneal cancer. Established multiple sets of animal models for studying cancer metastasis and a molecular imaging technology system for studying cancer invasion and metastasis using nano-fluorescent probes.

1. Liang XL, Su YD, Li XB, Fu YB, Ma R, Yang R, Wu HL, Cui YR, Li Y*(corresponding author). Prognostic factors of long-term survival and conditional survival analysis in MPM patients treated with CRS+HIPEC: A retrospective study of two centers. Ann Surg Oncol. 2024; 32(4): 2912-2922.

2. Liang XL, Su YD, Fu YB, Li XB, Ma R, Yang R, Wu HL, Li Y*(corresponding author). Effect of postoperative normothermic intraperitoneal chemotherapy on the prognosis of MPM patients receiving CRS+HIPEC: a single-center case-control study. Eur J Surg Oncol. 2024; 50(11): 108692.

3. Ji Z H, Zhao QD, Li Y*(corresponding author). The effects of HIPEC on survival of gastric cancer patients with peritoneal metastasis. J Surg Oncol. 2024; 130(6): 1190-1195.

4. Su YD, Ma R, Fu YB, Wu HL, Liang XL, Liu YT, Yu Y, Yang ZR, Li Y*(corresponding author). Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma. J Surg Oncol. 2024; 130(6): 1225-1234.

5. Liang XL, Li XB, Fu YB, Su YD, Ma R, Yang R, Wu HL, Li Y*(corresponding author). Research progress of malignant peritoneal mesothelioma with paraneoplastic syndrome: A review. J Surg Oncol. 2024; 130(3): 533-542.

6. Liu G, Ji ZH, Li XB, An SL, Zhang YB, Li B, Yu Y, Zhao X, Yang R, Li Y*(corresponding author). Outcomes following cytoreductive surgery and hyperthermic intraoperative thoraco-abdominal chemotherapy with diaphragm resection for peritoneal carcinomatosis: A retrospective cohort study. Ann Surg Oncol. 2024; 31(2): 1058-1068.

7. Yang R, Su YD, Ma R, Li Y*(corresponding author). Clinical epidemiology of peritoneal metastases in China: The construction of professional peritoneal metastases treatment centers based on the prevalence rate. Eur J Surg Oncol. 2023; 49(1): 173-178.

8. Ji ZH, Yu Y, Liu G, An SL, Zhang YB, Li B, Li XB, Yan GJ, Li Y*(corresponding author). Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients. Eur J Surg Oncol, 2021; 47 (6): 1411-1419.

9. van de Vlasakker VCJ, Lurvink RJ, Cashin PH, Ceelen W, Deraco M, Goéré D, González-Moreno S, Lehmann K, Li Y, Moran B, Morris DL, Piso P, Quadros CA, Rau B, Somashekhar SP, Sommariva A, van der Speeten K, Spiliotis J, Sugarbaker PH, Teo MCC, Verwaal VJ, Yonemura Y, Glehen O, de Hingh IHJT. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2021; 47(11): 2888-2892.

10. Huang CQ, Min Y, Wang SY, Yang XJ, Liu Y, Xiong B, Yonemura Y, Li Y*(corresponding author). Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget. 2017; 8(33): 55657-55683.

11. Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O, Sugarbaker PH, Morris D, Moran B, Gonzaletz-Moreno S, Deraco M, Piso P, Elias D, Batlett D, Ishibashi H, Mizumoto A, Verwaal V, Mahtem H. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol. 2016; 42(8): 1123-1131.

12. Fang M, Yuan JP, Peng CW, Li Y*(corresponding author). Collagen as a double-edged sword in tumor progression. Tumor Biol. 2014; 35(4): 2871-2882.

13. Zhong YJ, Shao LH, Li Y*(corresponding author). Cathepsin b-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). Int J Oncol. 2013; 42(2): 373-383.

14. Fang M, Peng CW, Pang DW, Li Y*(corresponding author). Quantum dots for cancer research: current status, remaining issues, and future perspectives. Cancer Biol Med. 2012; 9(3): 151-163.

15. Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Chen FL, Zhou YF, Xiong B, Yonemura Y, Li Y*(corresponding author). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011; 18(6): 1575-1581.

16. Li Y, Tang ZY, Hou JX. Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol. 2011; 9(1): 32-43.

17. Chen C, Peng J, Xia HS, Yang GF, Wu QS, Chen LD, Zeng LB, Zhang ZL, Pang DW, Li Y*(corresponding author). Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer. Biomaterials. 2009; 30(15): 2912-2918.

18. Huang W, Ding Y, Miao Y, Liu MZ, Li Y*(co-corresponding author), Yang GF. Synthesis and antitumor activity of novel dithiocarbamate substituted chromones. Eur J Med Chem. 2009; 44(9): 3687-3696.

19. Chen LD, Liu J, Yu XF, He M, Pei XF, Tang ZY, Wang QQ, Pang DW, Li Y*(corresponding author). The biocompatibility of quantum dot probes used for the targeted imaging of hepatocellular carcinoma metastasis. Biomaterials. 2008; 29(31): 4170-4176.

20. Al-Shammaa HAH, Li Y*(corresponding author), Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol. 2008; 14(8): 1159-1166.

21. Zheng F, Shi XW, Yang GF, Gong LL, Yuan HY, Cui YJ, Wang Y, Du YM, Li Y* (corresponding author). Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: results of an in vitro and in vivo study. Life Sci. 2007; 80(4): 388-396.

22. Huang W, Liu MZ, Li Y*(corresponding author), Tan Y, Yang GF. Design, synthesis, and antitumor activity of novel chromone and aurone derivatives. Bio Med Chem. 2007; 15(15): 5191-5197.

23. Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL, Liu YK, Tang ZY. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol. 2004; 130(8): 460-468.

24. Li Y, Tang ZY, Ye SL, Liu BB, Liu YK, Chen J, Xue Q*. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol. 2003; 129(1): 43-51.

25. Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH*. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol. 2001; 7(5): 630-636.

26. Sugarbaker PH, 杨智冉, 李雁*(通讯作者). 国际腹膜癌治疗指南：肿瘤细胞减灭术加腹腔化疗临床路径[J]. 中国肿瘤临床. 2020; 47(11): 541-551.

27. 李雁*(通讯作者), 许洪斌, 彭正, 崔书中, 吴畏, 梁寒, 朱正纲, 陆维祺, 李子禹, 徐惠绵, 刘骞, 赵赟博, 梁斌, 丁克峰, 吴玉梅, 张震宇, 杨国梁, 杨肖军, 魏少忠, 周全, 卢一艳. 肿瘤细胞减灭术加腹腔热灌注化疗治疗腹膜假黏液瘤专家共识[J]. 中华医学杂志. 2019; 99(20): 1527-1535.

28. 李雁*(通讯作者), 周云峰, 梁寒, 王华庆, 郝继辉, 朱正纲, 万德森, 钦伦秀, 崔书中, 季加孚, 徐惠绵, 魏少忠, 许洪斌, 锁涛, 杨树军, 谢丛华, 杨肖军, 杨国樑. 细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识[J]. 中国肿瘤临床. 2015; 42(4): 198-206.

2006, the First Prize of National Science and Technology Progress Award

2014, the First Prize of Science and Technology Progress of Hubei Province

2011, the First Prize of Science and Technology Progress of Hubei Province

2006. Second Prize of Science and Technology Progress of Hubei Province

2004, the Second Prize of Science and Technology Progress of Hubei Province

2004, the National Excellent Doctoral Dissertation Award by the Ministry of Education

2014, the Third Prize of Science and Technology of the China Anti-Cancer Association

2008, the ASCO (American Society of Clinical Oncology) International Development and Education Award

2007, The European Society for Medical Oncology Travel Award for Developing Countries

2020, the title of "Beijing Model Worker" by the Beijing Municipal People's Government

2019, the Commemorative Medal for celebrating the 70th anniversary of the founding of the People's Republic of China by the Central Committee of the Communist Party of China, The State Council and the Central Military Commission

2019, the 7th "Top Ten Health Guardians of the Capital" award by the Beijing Municipal Health Commission and Beijing Television

2017, the title of "People's Good Doctor of the Year" by the China Medical and Health Development Foundation

2017, the title of "Outstanding Good Doctor of Beijing" by China National Radio

2017, the top eight in the Best Poster Award at the 10th International Conference on Peritoneal Surface Malignancies

2016, the "Respect Life ·2016 Honor Doctor" - Anti-Cancer Specialty Elite Award by People's Daily, Global Daily and Life Times

2011-present, The sole representative from China on the Executive Committee of the Peritoneal Surface Oncology Group International (PSOGI), Deputy Editor-in-Chief of PSOGI World News, a quarterly newsletter with the latest news, views and announcements, Member of the standing committee, Radionotherapy physicians branch of Chinese Medical Doctor Association, Committee member, Committee on tumor metastasis of Chinese Anti-Cancer Association, Member of the International Association of Surgeons, Digestive and Oncology (IASGO), Member, the American Society of Clinical Oncology (ASCO), Executive director, China Biological Materials Association, Member of Nano-Oncology Committee of China Anti-Cancer Association, Executive director, the Council of Hubei Anti-Cancer Society, Deputy director, the Tumor Targeting Therapy Committee of Hubei Biomedical Engineering Society, Member of the sixth committee, the oncology chapter of Hubei medical association, Vice director, Oncology Branch of Hubei Physician Association, Deputy editor, Biomaterials, Editorial Board Member, Cancer Biology and Medicine, Editorial Board Member, Journal of New Medicine, Editorial Board Member, Chinese Journal of Clinical Oncology, Special correspondent, Chinese Medical Journal